Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SelK 2

Drug Profile

SelK 2

Alternative Names: Anti P-selectin glycoprotein ligand-1; Anti-PSGL-1-mAb - Tetherex; SelK-2

Latest Information Update: 24 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Selexys Pharmaceuticals
  • Developer Tetherex Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Antithrombotics; Monoclonal antibodies
  • Mechanism of Action P-selectin ligand protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Venous thromboembolism
  • Phase I Crohn's disease
  • Discontinued Multiple myeloma

Most Recent Events

  • 01 Oct 2019 Tetherex Pharmaceuticals completes a phase II trial in Venous thromboembolism in Bulgaria, Latvia, Lithuania, Poland and Ukraine (IV) (NCT03812328) (EudraCT2018-003122-88)
  • 20 Feb 2019 Phase-II clinical trials in Venous thromboembolism in Bulgaria, Ukraine, Poland (IV) (NCT03812328) (EudraCT2018-003122-88)
  • 11 Jun 2018 Discontinued - Preclinical for Multiple myeloma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top